R J Polzer

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

Thomas D. Gootz, Richard P. Zaniewski, S L Haskell et al. · Antimicrobial Agents and Chemotherapy · 1996 · 137 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies

Lindsay B. Avery, Mengmeng Wang, Mania Kavosi et al. · mAbs · 2016 · 114 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia

Paul H. Edelstein, M A Edelstein, Jie Ren et al. · Antimicrobial Agents and Chemotherapy · 1996 · 67 citations · Full text

Veterinary Medicine, Infectious Diseases, Microbiology +15

Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin

John Vincent, Jürgen Venitz, Rongyue Teng et al. · Journal of Antimicrobial Chemotherapy · 1997 · 65 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli

H Thadepalli, U Reddy, Seng‐Kee Chuah et al. · Antimicrobial Agents and Chemotherapy · 1997 · 35 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13